Table 3.
Stratified log-rank test for survival analysis in association with BACH2 expression level among GCB and non-GCB group
| Charateristics | BACH2 expression |
3-year OS (%) |
3-year PFS (%) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| High, n | Low, n | P | BACH2-high | BACH2-low | P | BACH2-high | BACH2-low | P | ||
| Clinical stage | I/II (n = 44) | 21 | 23 | 0.315 | 80.7 | 100 | 0.0595 | 73.1 | 91.3 | 0.144 |
| III/IV (n = 32) | 19 | 13 | 61.8 | 71.4 | 51.3 | 57.5 | ||||
| IPI score | 0–2 (n = 51) | 25 | 26 | 0.368 | 89.3 | 94.7 | 0.0864 | 76.4 | 82.3 | 0.122 |
| 3–5 (n = 25) | 15 | 10 | 46.7 | 75.0 | 40.0 | 78.7 | ||||
| LDH | Normal (n = 32) | 15 | 17 | 0.391 | 92.3 | 100 | 0.0624 | 68.9 | 86.9 | 0.100 |
| Elevated (n = 44) | 25 | 19 | 60.6 | 80.0 | 58.2 | 74.0 | ||||
| sIL-2R† | Normal (n = 15) | 6 | 9 | 0.325 | 100 | 100 | 0.0265 | 83.3 | 88.9 | 0.0628 |
| Elevated (n = 59) | 32 | 27 | 64.8 | 88.9 | 56.5 | 77.8 | ||||
| Hans' criteria | GCB (n = 38) | 21 | 17 | 0.646 | 63.2 | 90.9 | 0.0248 | 60.2 | 90.9 | 0.0789 |
| Non-GCB (n = 38) | 19 | 19 | 81.4 | 91.7 | 64.5 | 70.6 | ||||
| BCL2 | Positive (n = 52) | 29 | 23 | 0.420 | 69.7 | 93.3 | 0.0303 | 60.4 | 74.0 | 0.0708 |
| Negative (n = 24) | 11 | 13 | 81.8 | 87.5 | 72.7 | 84.6 | ||||
| MUM1 | Positive (n = 37) | 19 | 18 | 0.828 | 81.4 | 92.3 | 0.245 | 64.3 | 80.5 | 0.612 |
| Negative (n = 39) | 21 | 18 | 63.4 | 90.0 | 60.4 | 79.7 | ||||
| MIB-1 index‡ | ≥ 90% (n = 17) | 12 | 5 | 0.0811 | 54.5 | 84.0 | 0.214 | 46.9 | 75.0 | 0.251 |
| < 90% (n = 58) | 27 | 31 | 84.0 | 89.5 | 72.0 | 81.3 | ||||
| MYC expression | High (n = 37) | 24 | 13 | 0.0375 | 59.9 | 85.7 | 0.0480 | 57.6 | 83.3 | 0.365 |
| Low (n = 39) | 16 | 23 | 93.8 | 93.8 | 70.0 | 80.0 | ||||
†
In two cases sIL-2R was not assessed.
‡
In one case MIB-1 index was not assessed.
IPI, international prognostic index; LDH, lactate dehydrogenase; OS, overall survival; PFS, progression-free survival; sIL-2R, soluble inteleukin-2 receptor.